An Intriguing Approach to Slow Alzheimer’s Shows Mixed Results

The New York Times
Original Story by The New York Times
November 16, 2026
An Intriguing Approach to Slow Alzheimer’s Shows Mixed Results

In the largest trial to date evaluating a headset that delivers flickering light and sound to slow Alzheimer’s, results were mixed: the 12-month study found no overall cognitive advantage over a sham device for participants with mild to moderate disease. Moderate-stage patients showed no benefit, while those with milder impairment suggested slower decline when used near daily for about an hour. The findings create a path to FDA consideration for the mild subgroup, though the overall trial underscores the challenge of achieving a robust effect across the full spectrum of disease. The company Cognito Therapeutics intends to pursue regulatory approval, contingent on demonstrating benefit in mildly affected individuals.

Dive Deeper:

  • The device, named Spectris, relies on audiovisual stimulation to elicit brainwave responses with the aim of preserving neurological function and aiding waste clearance in the brain.

  • The trial enrolled participants with mild to moderate Alzheimer’s and compared the active headset against an inactive placebo (sham) over 12 months, with results presented at a major Alzheimer’s conference.

  • Overall, the study did not meet its primary endpoint, showing no slower cognitive decline in the active group compared with the sham across the full participant set.

  • Moderate-stage patients received no measurable benefit from the device, according to data disclosed by Cognito Therapeutics.

  • Among mildly impaired patients, data generally indicated a potential slowing of decline when the device was used regularly, particularly close to the recommended 60 minutes per session.

  • Cognito’s CEO Christian Howell attributed the failure to moderate patients’ lack of response, while signaling a clear regulatory pathway for the mild subgroup if results hold.

  • The company announced intentions to seek FDA approval, citing the observed signal in the mild population as a basis for pursuing regulatory clearance.

Latest News

Related Stories